1. Home
  2. NCNA vs DRMA Comparison

NCNA vs DRMA Comparison

Compare NCNA & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$1.11

Market Cap

5.5M

Sector

Health Care

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

N/A

Current Price

$1.12

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCNA
DRMA
Founded
1997
2014
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
5.6M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
NCNA
DRMA
Price
$1.11
$1.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 56.4K
18.3K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.95
52 Week High
$6.16
$4.66

Technical Indicators

Market Signals
Indicator
NCNA
DRMA
Relative Strength Index (RSI) 36.11 36.47
Support Level N/A $0.95
Resistance Level $1.40 $1.40
Average True Range (ATR) 0.09 0.06
MACD -0.02 0.00
Stochastic Oscillator 28.97 10.00

Price Performance

Historical Comparison
NCNA
DRMA

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: